Glioblastoma is the most common primary brain tumour in adults, and certainly one of the most lethal human tumours ([@bib40]) Its incidence is about 3 new cases per 100 000 population per year, the median age of diagnosis is 64 years and most of the patients have passed away 2 years following diagnosis ([@bib76]). Unlike low-grade gliomas, complete surgical removal of glioblastoma is impossible because of the infiltrative nature of the disease and the functional vulnerability of the brain. Postoperative radiotherapy is the standard adjuvant therapy offered worldwide. Following surgery alone, the median survival is 6 months and increases to 12 months with the addition of radiotherapy ([@bib85]). Because of the extent and the location of the disease adjacent to critical brain areas or because of the poor performance status of patients at diagnosis, surgery is often omitted and radiation is offered as the main treatment option.

Attempts to improve the efficacy of radiotherapy with the addition of chemotherapy, mainly nitrosoureas (BCNU, CCNU), go back to the early 1970s. In [@bib22] *et al* in a randomised trial failed to show a benefit from the addition of CCNU and procarbazine to radiotherapy. In the same year, an RTOG study provided evidence that radiochemotherapy with BCNU or methyl-CCNU or DTIC was superior to radiotherapy alone ([@bib12]). The benefit, however, provided by nitrosoureas was limited and questionable as stressed in subsequent randomised trials ([@bib39]; [@bib18]; [@bib88]; [@bib16]). The only therapeutic innovation that had an impact in the management of glioblastomas appeared in 2005, when a randomized study showed that temozolomide improved the median survival of patients undergoing radiotherapy by 2.6 months ([@bib93]). In a more recent analysis of the EORTC-NCIC trial on 573 patients, the 2-year survival was 27.2% in the temozolomide group *vs* 10.9% in the radiotherapy-alone group ([@bib92]). Nowadays, postoperative radiotherapy with daily administration of TMZ is the gold standard for patients with glioblastomas, although the efficacy of this therapy remains disappointing and attempts to improve the median survival using the combination of TMZ with other drugs, such as motexafin gadolinium ([@bib9]), has failed, with the 5-year survival remaining \<10%.

In the era of targeted therapies, there is an increasing optimism that the identification of key molecular pathways may lead to major improvements in the management of this highly lethal disease. Glioblastomas, being highly angiogenic tumours, were thought to be susceptible to antiangiogenic therapy. Indeed, in 2009, bevacizumab (BVZ), an anti-VEGF humanised monoclonal antibody, received accelerated approval by the FDA for the treatment of recurrent glioblastoma following a randomised phase II study ([@bib62]). In the most recent randomised RTOG 0825 trial, however, the addition of BVZ (10 mg kg^−1^ every 2 weeks) to standard chemoradiation improved the progression-free interval but had no effect on overall survival ([@bib32]). Recent studies on newly diagnosed glioblastoma patients showed that the same results and sub-population of patients with better response to BVZ treatment could not be predicted by the molecular data ([@bib82]). The benefit from BVZ therapy seems to be confined to oedema reduction and a cut down on the usage of corticosteroids ([@bib94]).

Epidermal growth factor receptor-mediated oncogenic signalling is active in most human carcinomas and has become a target for therapeutic interventions. Indeed, anti-EGFR1 moAb and pharmacological tyrosine kinase inhibitors have shown important clinical activities in the colon, lung and head and neck cancer. About half of glioblastomas bear *EGFR* gene amplification and receptor overexpression ([@bib38]). Mutation of *EGFR* with constitutive activation of the pathway is also quite common. Although the efficacy of such agents as single therapy is limited ([@bib99]), randomised trials in combination with radiotherapy are missing.

The unique nature of the glioblastoma cells to be resistant to apoptotic stimuli, their death occurring rather through autophagy ([@bib105]; [@bib50]), suggests that autophagy-interfering agents in combination with radiation and temozolomide may represent a new strategy to test. This hypothesis becomes much more relevant under the new light shed by studies, suggesting that autophagy is the main pathway exploited by cancer stem cells to survive and accelerate their renewal ([@bib45]; [@bib34]; [@bib6]). Glioma stem cells is considered the most radioresistant cell population and autophagy targeting may assist to eradicate the disease ([@bib89]; [@bib110]). This review aims to critically present our knowledge regarding the autophagic response of glioblastoma cells to radiation and TMZ and to delineate eventual research directions to follow in the quest of improving the curability of this incurable, as yet, disease.

Autophagy and autophagic death
==============================

Macroautophagy (herein stated as autophagy for simplicity) is a major cell pathway dedicated to a continuous renovation of cell constituents through the degradation and recycling of long-lived or damaged proteins and even of entire organelles, such as ribosomes, mitochondria, endoplasmic reticulum and Golgi apparatus ([@bib57]; [@bib23]). During autophagy double-membrane vesicles are formed, which sequester portions of the cytoplasm and fuse with endosomal and lysosomal vesicles ([@bib108]). Beclin 1 and ULK (UNC-51-like kinases) proteins are important autophagosome initiation proteins, whereas LC3A, LC3B and LC3C are key structural components of the autophagosomes, which are extensively used for the experimental study of autophagy ([@bib48]; [@bib102]), whereas the difference in expression levels and of subcellular distribution and kinetics of these proteins may be an indication of different roles during autophagy ([@bib31]; [@bib59]).

Autophagy-related protein 8 (Atg8/LC3), an ubiquitin-like protein, has different homologues encoded by different chromosomes in animals, including MAP1LC3A, B and C, as well as the GABARAP proteins, which are the most important constituents of the autophagosomal membranes ([@bib90]). Most of them are produced as a pre-LC3 25--30 kDa protein that are cleaved by the autophagophagin (Atg4) to the soluble form of LC3, the 18 kDa LC3-I protein. Following an ubiquitination-like reaction, the exposed C terminus conjugates to the head group amine of phosphatidylethanolamine (PE) through an amide bond, becoming the so-called membrane-bound 16 kDa LC3-II form that forms both the outer and inner autophagosome membranes. The p62/sequestrosome protein is the main carrier of the waste material to the LC3-II membranes that engulf the complex within a mature autophagosome ([@bib52]). This is followed by fusion with lysosomes and digestion of the autophagolysosomal content, resulting in the disintegration of intracellular waste and at the same time providing energy to the cell. During this process, LC3-II protein can be delipidated by Atg4 proteases and liberated in the cytoplasm. The different forms of LC3 proteins and the kinetics of the p62 protein can be detected by western blot or confocal microscopy methods, providing important tools to study the autolysosomal flux in normal cells and cancer cells under various stresses ([@bib56]).

Under energy-demanding stress conditions, such as starvation or hypoxia, autophagy is accelerated ([@bib58]; [@bib7]). On the one hand, excessive intensification of this very process may lead to intolerable cytoplasmic digestion, leading to cell exhaustion and death. On the other hand, accumulation of autophagosomes under stress, which block their fusion with lysosomes (e.g., hydroxychloroquine or 3-methyadenine), may also lead to autophagic death ([@bib55]; [@bib84]). Autophagy is called type II programmed cell death pathway, which is a distinct pathway compared with the apoptotic type I death pathway triggered by DNA or membrane damage followed by release of caspases from the mitochondria. Autophagy is, therefore, a balance that weighs between renovation, energy acquisition, survival and cell death, according to the external or internal stimuli received.

Cancer cells have an increased autophagic activity as shown in a series of clinicopathological studies, where LC3 and autophagy-initiating proteins are overexpressed, a feature linked with aggressive clinical behaviour ([@bib91]; [@bib31]; [@bib59]). In a recent study, we noted that overexpression of LC3A in the form of stone-like cytoplasmic structures was linked to poor postradiotherapy prognosis in a series of patients with glioblastoma ([@bib71]). Since several decades we know that an inert apoptotic machinery is a very common phenomenon in cancer cells, allowing them to escape death after exposure to cytotoxic chemotherapy and radiotherapy ([@bib41]). Evasion from apoptosis is a well-established phenomenon in gliomas and glioblastomas ([@bib61]). Therefore, autophagic death is an alternative pathway to pursue in an attempt to eradicate glioma cells exposed to cytotoxic stress ([@bib119]).

Radiotherapy and autophagy in gliomas/glioblastomas
===================================================

Several experimental studies have confirmed that glioma and glioblastoma cells exhibit important resistance to apoptosis after exposure to ionising radiation. Expression status of apoptosis-related genes such as *PTEN* may be involved in the phenomenon ([@bib63]), and interference with various signaling pathways such as STAT3 and EGFR may restore the ability for apoptotic death ([@bib30]).

The study by [@bib104] is probably the first to show that irradiation of human glioblastoma cells results in enhanced autophagy, whereas no apoptosis was evident in radiosensitive or radioresistant cell lines. [@bib44] subsequently confirmed that ionising radiation induces cell cycle arrest and autophagic death, but not apoptosis, in glioma cell lines. Moreover, [@bib47] suggested that autophagy is a pathway to cell death after glioma irradiation. In 2005, a study from the MD Anderson Cancer Center showed that DNA-protein kinase (DNA-PK)- (enzyme involved in the repair of DNA double-strand breaks) deficient glioma cells suffered massive autophagic death even after low doses of radiation ([@bib17]). Intact DNA-PK pathway prevented autophagic death, but cells still exhibited a low apoptotic tendency. Of interest, induction of autophagy using siRNA against DNA-PK sensitised glioblastoma cell lines ([@bib114], [@bib115]). An additional study using particle radiation, which mainly kills through DNA double-strand damage, supports the suggestion that DNA repair disabling is a potent stimulus not only for apoptotic death but also for autophagic death in gliomas ([@bib46]).

The Akt/m-TOR is recognised as a major pathway regulating autophagy. Inhibitors of Akt/m-TOR activity, such as rapamycin analogues, intensify the autophagic process ([@bib70]). This pathway is often upregulated in tumours, including glioma ([@bib1]). Akt inhibitors induce autophagic death, but not apoptotic death, in both radioresistant and radiosensitive U87 glioma cell lines and enhance sensitivity to radiation ([@bib27]). In the same cell line, [@bib5] found that high LET radiation kills cells through autophagy. [@bib71] further confirmed that Akt inhibition radiosensitises primary human glioblastoma stem-like cells. Moreover, silencing of *EGFR*, an activator of PI3K/Akt/mTOR pathway, with simultaneous induction of autophagy led to better response to IR and suppressed migration in the T98G cell line ([@bib77]). These results are further supported by [@bib33], who showed that the growth of EGFRvIII-activated glioblastoma was blocked after treatment with CC214-1 and CC214-2, which are inhibitors of mTORC1 and mTORC2. The study by [@bib15] suggested that arsenic trioxide also enhances the activity of radiation in glioma cell lines by augmenting the autophagic cell death, which is also supported by [@bib11], who showed that glioblastoma stem cells differentiated into non-tumourigenic cells as a result of autophagy induction, after inhibition of PI3K/Akt and stimulation of mitogen-activated protein kinase pathway using arsenic trioxide and metformin, respectively. Rapamycin has also been shown to induce differentiation of glioma-initiating cells and increase their radiosensitivity by activating autophagy ([@bib114], [@bib115]).

Furthermore, research related to NF-*κ*B, a factor that suppresses autophagy in response to TNFa ([@bib20]), showed that treatment of glioma cells with pitavastatin (inhibitor of NF-kB) resulted in autophagic death but not apoptotic death, and empowered the activity of radiation ([@bib95]). Nuclear factor-*κ*B is a transcription factor negatively regulating apoptotic death. Early phase blockers of autophagy, such as 3-methyladenine (3-MA), counteracted the cytotoxic effect of radiation and of the combination with pitavastatin.

A variety of researches focused on glioma radiosensitisation via autophagy suppression. [@bib111] exhibited that suppression of *ATG5* using siRNA or suppression of autophagy using 3-methyladenine increased the radiosensitisation effect of gliomas after *STAT3* inhibition. Moreover, according to [@bib106], the resistant clones of glioma stem cells bear high expression levels of early growth response 1 that induce autophagy. Additionally, mitochondrial isoenzyme of NADP^+^-dependent isocitrate dehydrogenase siRNA-transfected A172 glioma cells were sensitised after inhibition of autophagy ([@bib54]).

There is, therefore, important evidence that in glioma cells autophagic death is the most common pathway exploited by radiation compared with apoptosis. Although reactive autophagy may occur in the context of a cell survival response to radiation, which may represent a radioresistance pathway, augmenting the autophagic response through combination with Akt/mTOR inhibitors would shift the balance to death. DNA repair enzyme inhibitors seem also to facilitate radiation-induced autophagic death, and at the same time restoring to a certain extent the apoptotic pathway. The fact that early phase autophagy inhibitors also sensitise glioma cells to radiation ([@bib68]) is not contradictory to the whole concept, as abrogating low-level autophagy that keeps the balance to the survival side is expected to increase vulnerability to radiation. Late phase autophagy inhibitors that block autophagolysosomal formation are also expected to be radiosensitisers as they abrogate cytoprotective autophagy and load the cell with waste material, resulting in autophagy-mediated death.

Temozolomide and autophagy in gliomas/glioblastomas
===================================================

One of the first studies regarding the role of autophagy in malignant gliomas showed that TMZ at clinically relevant concentration of 100 *μ*M induces autophagy rather than apoptosis in malignant glioma cells, as shown by the accumulation of the LC3 protein on autophagosomal membranes. [@bib64] suggest that TMZ in combination with chloroquine could inhibit the growth and apoptosis of glioblastomas, whereas autophagy suppression leads to the abolishment of the combination effect of TMZ and chloroquine ([@bib64]). Moreover, blockage of autophagy at an early step by 3-MA prevented the accumulation of autophagosomes and suppressed the cytotoxic effect of TMZ. [@bib112], however, suggested that autophagy has a protective role in gliomas as TMZ/curcumin treatment in combination with 3-MA leads to a reduction of cell viability. Nevertheless, bafilomycin that blocks autophagy at a late step, by preventing the fusion of mature autophagosomes with lysosomes, sensitised glioma cells to TMZ by inducing apoptotic rather than autophagic death.

These studies suggest that autophagy and drug interaction is a very complex process. Blockage of autophagosome formation abrogates the autophagic death induced by TMZ. On the contrary, non-functional accumulation of autophagosomes (induced by TMZ and blocked by late phase autophagy drugs) releases an apparent pre-existing obstacle in the apoptotic pathway, driving cells to apoptotic death. [@bib65] suggested that as glioblastoma cells are resistant to apoptosis, blocking targets that keep autophagy suppressed, such as mTOR, may enhance the activity of TMZ-induced autophagic death ([@bib113]).

An important link between TMZ-induced autophagic death and cell metabolism has been subsequently brought forward by [@bib51]. In experiments in multiple glioma cell lines, TMZ consistently induced autophagy in parallel with an increase of ATP production. This ATP surge could not be blocked by glucose starvation but was blocked by agents blocking early steps of autophagy (methyladenine and *beclin 1* siRNA). As this inhibition resulted in micronucleation, it was suggested that autophagy-induced ATP surge counteracts the TMZ-induced autophagic death. Indeed, administration of pyruvate abrogated the activity of early phase autophagy inhibitors and enhanced glioma cell survival. Small molecules, such as dasatinib, which antagonise the ATP binding pocket of abl, kit or EGFR proteins, induce autophagic cell death in glioblastoma cells and have synergistic effect with TMZ ([@bib73]). Moreover, the association between metabolism and mitochondria with the efficacy of TMZ is supported by a several recent studies. [@bib109] showed that the expression of ATAD3A, a mitochondrial protein ATPase (ATAD3A), is a prognostic factor for glioblastomas and a predictor of TMZ or radiation resistance ([@bib109]). Another study that supports the hypothesis of association between the function of mitochondria and TMZ showed that metformin, which inhibits mitochondrial electron transport chain complex I, enhances the cell cytotoxicity of TMZ ([@bib87]).

It seems, therefore, that although exacerbation of autophagy is a death pathway exploited by TMZ, the energy released by this very process counteracts TMZ efficacy. Overactivity of the autophagic pathway in the context of a cell-cytoprotective mechanism against TMZ can be at the same time the cause of temozolomide-induced cell death. Abrogation of the end point of such an autophagic-protective mechanism, which is energy production, inevitably shifts the balance to increased autophagic death. In pathological studies, the majority of glioblastoma cases examined had an upregulated autophagic pathway at diagnosis ([@bib3]; [@bib81]), with overexpression of LC3, beclin 1 and ULK proteins ([@bib31]), presumably as an indispensable pathway for energy acquisition under the stressful metabolic demands of an accelerated growth. Any stressor, like TMZ, that further accelerates autophagy may result in autophagic death by disrupting a delicate balance between energy replenishment and suicide autophagy. The synergism found between TMZ-induced autophagy and autophagy-mediated killing effect of oncolytic adenoviruses ([@bib107]; [@bib97]) may also be explained under this point of view.

An interesting observation from the clinicopathological studies is that a glioblastoma group with low levels of LC3 and beclin 1 has a poorer prognosis and may be more resistant to TMZ, although this hypothesis demands further confirmation in larger studies. A study by [@bib25] provides important insights into this phenomenon. Following separation of CD133-positive and -negative glioblastoma cells from a freshly resected tumour, positive cells (representing glioblastoma stem cells) had lower LC3-II and beclin 1 levels compared with negative ones and were more resistant to TMZ ([@bib25]). Both cells, however, were resistant to caspase-3 induction following incubation with TMZ. An important hypothesis that emerges from these studies is that, although autophagic death is a main pathway of glioma cell death after exposure to TMZ, glioma stem cells may have an autophagic machinery refractory to the activity of the drug and, therefore, more easily survive under exposure to TMZ, leading subsequently to tumour repopulation and growth.

The above data contrast the study by [@bib68] where CD133-positive cells seem to upregulate autophagy more potently than negative cells after exposure to radiation and to the finding that autophagy inhibition sensitises the stem cell sub-population to radiation. Similar results have been reported by [@bib101], who supports that high level of CD133 population and high rate of autophagy lead to a poor prognosis in astrocytomas ([@bib101]). Although further studies are demanded to elucidate this discrepancy that may be cancer cell line-dependent, differences in the mechanism of autophagy induction between radiation and TMZ can also underlie. In addition, it is stressed that for currently applied experimental techniques, it is difficult to distinguish between autophagosomal or autolysosomal non-functional accumulation *vs* intensified autophagy. Moreover, as LC3A and LC3B are distinct proteins with different response at various stimuli, studying the autophagic response with nonspecific LC3 subtype markers may provide confusing results and mask specific response patterns that may be important to TMZ activity.

In any case, restoration or protection of the autophagic flux may be important in sensitising cells to TMZ. Methylation of the promoter of *Beclin 1* gene has been reported to be a common event in breast cancer ([@bib67]). Whether hypomethylating agents can be of value to restore autophagic responsiveness in glioma stem cells and sensitivity to TMZ is a sound hypothesis. 5-Aza-20-deoxycytidine, a potent demethylating agent, is an autophagy promoter ([@bib14]). Although it is unknown whether demethylating agents can restore autophagy in glioblastomas, we know that they restore the expression of genes involved in apoptosis ([@bib21]) like caspase-8, which is hypermethylated in stem cell-like glioma cells ([@bib10]). However, differentiation-inducing agent inhibitors of histone deacetylase, such as valproic acid ([@bib78]), are potent inducers of autophagy in glioma cells, enhancing autophagic cell death but not apoptosis ([@bib26]). Whether such agents can target TMZ-resistant glioma stem cells is another hypothesis to test. Carbamazepine is also another drug that increases the autophagic flux and protects normal tissues against radiation ([@bib53]), presumably due to restoration of the radiation-induced autophagy blockage ([@bib118]).

Restoring apoptosis
===================

Another important approach aside to autophagy death pathway manipulation is to interfere with the molecular pathways aiming to overcome the relative resistance of glioma cells to apoptotic death. Both radiotherapy and TMZ are DNA-damaging agents. Radiotherapy induces both DNA single- and double-strand breaks, the kinetics and fidelity of repair of which define cell survival and clonogenic ability ([@bib74]; [@bib75]). Whether apoptosis, mitotic catastrophe or senescence follows defective DNA repair is an outcome defined, at least partially, by the oncogene and apoptosis-related gene activity in cancer cells ([@bib98]; [@bib74]). Gene therapy or small molecules restoring p53 function increase the radiation-induced apoptosis in cancer cells, as well as in glioblastomas ([@bib100]; [@bib80]). Temozolomide is also a DNA-damaging agent. Following its conversion to 5-aminoimidazole-4-carboxamide, it delivers methyl groups to DNA, resulting in the formation of *O*^6^-methylguanine, which mispairs erroneously with thymine (instead of cytosine) during DNA replication, resulting in DNA double-strand break formation ([@bib28]). The death pathway that follows depends on the gene expression profile of the cancer cell, the p53, PUMA and bcl-2 family of protein expression status being decisive for the activation of the apoptosis pathway under exposure to temozlomide, even of glioma stem cells ([@bib35]; [@bib72]).

Gene therapy or novel therapeutic agents that restore the apoptotic machinery in gliomas may prove to be of importance in reactivating apoptotic death induced by both ionising radiation and TMZ. Inhibitors of the PDGFR seem to initiate the apoptotic pathway in apoptosis-resistant glioblastoma cells ([@bib116]). Anti-EGFR therapy has been reported to sensitise CD133-positive glioma cells to radiation, presumably by restoring their apoptotic ability ([@bib19]). Specific inhibitors of the checkpoint kinases Chk1 and Chk2 reverse the radioresistane of these cells ([@bib4]). Drugs targeting the mitochondrial pore, such as lonidamine, have been shown to induce apoptotic death in TMZ-resistant glioma cells ([@bib66]). [@bib13] found that *Sirtuin 1* gene is exclusively expressed in CD133-positive radioresistant stem cells and that silencing this gene improves curability in experimental models. Agonist antibodies of the TRAIL death receptor 5 that induce apoptosis are also shown to improve the efficacy of radiotherapy and TMZ ([@bib24]). Gene therapy approaches, such as introduction of the caspase-8 gene or IL-24 gene, may be also useful in restoring apoptosis of glioma cells ([@bib96]; [@bib103]).

Which autophagic death?
=======================

The above data suggest that glioma and glioblastoma cells exhibit an autophagic response after exposure to ionising radiation and TMZ. This assumption is based on the increased accumulation of LC3-positive autophagosomes. Such a finding, however, does not necessarily mean an intensified 'functional autophagy\'. In fact, disruption of the lysosomal and autophagosomal fusion may also result in LC3-positive autophagosomal accumulation, without intensification of the production of new autophagosomes. This is an important point we need to clarify regarding the actual effect of ionising radiation on the autophagic machinery. Autophagic flux studies in cancer cells are demanded to elucidate the phenomenon, and such studies are absent in the literature. Our studies in normal fibroblasts and endothelial cells suggest that radiation results in an early blockage of the autophagic flux within the first days of irradiation ([@bib49]). The increase of LC3-II membrane-bound form in the soluble fraction of cells instead of the pellet fraction and the sharp increase of p62 protein (that normally disintegrates in the autophagolysosomal environment once incorporated) strongly suggest that radiation induces a non-functional accumulation of autophagosomes in cells, inducing autophagic death in a similar way that late phase autophagy blockers (such as chloroquine and bafilomycin) do. In fact, restoration of autopagic flux protects normal cells from radiation death.

Whether this phenomenon also applies in cancer cells or whether these sustain a resistant attitude against radiation-induced autophagy flux blockage demands thorough investigation. Preliminary experiments show that the response of cancer cells seems to be cell line- and radiation dose-specific (unpublished data). A biphasic relation linking radiation dose levels and the autophagic survival/death balance in cancer cells cannot be excluded. Lower doses, especially in radioresistant cells, could trigger a functional autophagic response with a rather cytoprotective role providing energy to the cells. In contrast, higher doses may disrupt the autophagic process by downregulating autophagy gene expression and/or by blocking autophagosome/lysosomal interaction shifting the balance to an autophagic death because of an accumulation of waste. This, however, is nothing more than a hypothesis that should be thoroughly examined, as different fractionation of radiotherapy may have a different effect on autophagy and may synergise better with different autophagy-interfering agents. Nevertheless, in a recent study in prostate cancer we provided a strong evidence that such a hypothesis is valid, as a radioresistant cell line intensified its autophagic flux after low-dose radiation, whereas this was blocked in a radiosensitive one using the same radiation dose ([@bib59]). It may be, therefore, that radioresistant tumours continue or accelerate their autophagic flux when exposed to low dose per fraction (i.e. within the range of standard 2 Gy per day fractionation), whereas larger fractions (hypofractionation) may block the autophagic flux and at least partially overcome radioresistance. Silencing of the LC3A gene results in important radiosensitisation, suggesting that autophagy is eventually a pathway of survival following irradiation of radioresistant cells and tumours ([@bib60]).

Nowadays, it is more than clear that autophagy is overactive in a large fraction of tumours, including gliomas ([@bib10]), and cell death features representative of an autophagic exhaustion of the cytoplasmic material are commonly evident in the form of stone-like cytoplasmic structures. Indeed, we identified the formation of the so-called LC3A-positive 'stone-like structures\' in various cancer tissues, showing a complete elimination of the cytoplasm of cells and its substitution by one or more dense structures of amorphous undigested LC3-positive material ([@bib91]). This feature, also evident in human glioblastomas, was inducible under acidic conditions and glucose antagonism, showing the existence of this type of autophagic cell death in glioblastomas ([@bib10]). This autophagic death path presumably demands functional and overactivated autophagy to uncontrollably consume the cytoplasmic content, shifting the balance from autophagic cytoprotection to autophagic death. Thus, as cancer cells use functional upregulated autophagy to survive the hypoxic and overall unfavorable tumour environment, further exogenous induction of functional autophagy, for example, through Akt/mTOR inhibitors, may push the balance towards cytoplasmic exhaustion and autophagic death.

It can be, therefore, suggested that autophagic death is not a single phenomenon but is rather characterised by at least two distinct paths: (i) the excessive autophagic activity resulting in stone-like structure formation (functional autophagic death) by exhaustion of the lysosomal potential and; (ii) the intolerable accumulation of waste non-functional autophagosomes (non-functional autophagic death) by abrogation of lysosomal fusion. Whether this latter path represents a link of autophagy with apoptosis, necrosis or mitotic catastrophe induction or it represents an entirely distinct death pathway is unknown.

The paradoxical sensitisation by both inducers and blockers
===========================================================

Nevertheless, both 'functional\' and 'non-functional\' autophagic death pathways triggered by radiation and TMZ can be boosted by early or late phase autophagy blockers and by autophagy inducers. This paradox can be explained as follows:

Early phase autophagy blockers prevent the formation of autophagosomes, blocking therefore an important source of energy and the cytoprotective effect of a controllable functional autophagy. This, on the one hand, leads *per se* to the death of a varying fraction of tumour cells, the survival of which depended on functional autophagy. On the other hand, by blocking autophagosome formation tumour cells enter a state of energy deficit and excessive loading with damaged proteins and organelles that radiation or TMZ produces, facilitating the apoptotic death effect of these agents. Thus, early autophagy blockers may activate a link with apoptosis-like pathways. For such therapeutic approaches, apoptosis restoration policies may secure a superadditive effect.Late phase autophagy blockers, for example, those that allow the formation of autophagosomes but block their fusion with lysosomes, repress by one hand the acquisition of energy through autophagy and on the other hand load the cell with waste non-degradable autophagic vesicles. Thus, similarly to early phase blockers, they kill a varying percentage of tumour cells through energy deprivation and waste overloading. If a radiotherapy schedule and/or TMZ also induces non-functional autophagosome formation, the synergistic effect with the energy austerity effect or with the autophagosome accumulation is antagonistic or at least additive. However, if a radiotherapy schedule is given in those small fractions to induce functional autophagy, the intensified accumulation of autophagosomes using late blockers would result in superadditive effect. In fact, a combination of an early phase autophagy inducer with a late phase blocker seem an appealing therapeutic proposal.Autophagy inducers could not only target tumour cells with increased autophagy but also tumour cells with reduced autophagy. In tumour cells with active autophagy, augmentation of autophagy may shift the balance to functional autophagic death through lysosomal exhaustion and cytoplasmic degradation (stone-like death). If radiation and TMZ is scheduled to induce functional autophagy, autophagy inducers administered concurrently with radiation will accelerate functional autophagic death. If radiation and TMZ are scheduled to induce non-functional autophagosome accumulation, administration of autophagy inducers immediately before radiochemotherapy may enhance the non-functional autophagic death.

Clinical experience
===================

Clinical experience with autophagy-manipulating agents in the treatment of glioblastoma is limited. Chloroquine ([@bib55]), presumably because it is already availabile in the clinical practice as an antimalaria agent ([@bib37]), is the only autophagy inhibitor studied for the treatment of glioblastoma patients. In a phase II clinical trial, the administration of hydroxychloroquine to patients with glioblastoma undergoing radiotherapy with temozolomide confirmed an increase of autophagic vacuoles and of the LC3-II form in the peripheral blood cells, supportive of an antiautophagic activity, but the haematological toxicity of the regimen was unacceptable and the benefit in terms of survival was not evident ([@bib83]). A small pilot study on the combination of chloroquine with radiation for the treatment of recurrent glioblastoma confirmed the feasibility of the regimen and the authors claimed encouraging treatment outcomes ([@bib8]). The recent observation that the acidic extracellular pH neutralises the autophagy-inhibiting activity of chloroquine stresses the importance of the development of potent autophagy inhibitors, the activity of which is independent or even better take advantage of the intratumoral hypoxic and acidic conditions ([@bib79]).

Mammalian target of rapamycin inhibitors have multiple biological activities, including the induction of autophagy ([@bib43]). Such agents have been introduced in the clinical practice for the treatment of renal carcinoma ([@bib2]), and several clinical trials have investigated the activity mTOR inhibitors in patients with glioblastoma. Temsirolimus, for example, showed clinical efficacy in one-third of patients treated for recurrent glioblastoma ([@bib29]). [@bib86] combined everolimus in combination with radiotherapy and TMZ in 18 patients, showing a metabolic effect of everolimus in most patients, as detected with fluorodeoxyglucose PET scan. More recently, the authors reported a phase II study on 100 patients, which, however, did not detect any beneficial effect in terms of survival ([@bib69]). An interesting phase II study by [@bib36] administered BVZ with everolimus after radiochemotherapy for 68 glioblastoma patients ([@bib36]). The progression-free survival interval compared favorably with the authors\' previous experience.

Important issues to resolve
===========================

It is evident that although we know that radiation and TMZ kill cells through autophagy, it is unclear which of the functional or non-functional autophagic death pathway is followed. It is very important to investigate the role of radiotherapy fractionation on the autophagic pathways that this activates. Several tumours, such as gliomas, melanomas or even prostate cancer, exhibit a higher sensitivity to large radiotherapy fractions. It may be that small radiotherapy fractions (around 2 Gy) can simply stimulate functional autophagy in such cells, triggering therefore a cytoprotective pathway during the fractionated course of radiotherapy. Larger fractions can block autophagic flux leading to non-functional accumulation of autophagosomes, so that in such radiation scheme self-sensitises cells to its effect.

If such a differential effect on autophagy exists, then the choice and sequence of autophagy-interfering agent for combined administration should be made according to the fractionation of radiotherapy we wish to apply. The same principle can be also applicable for TMZ as the short schedule of 200--250 mg m^−2^ × 5 days every month or the prolonged schedule of 70 mg m^−2^ per day continuously used in the clinical practice may have a different effect on the autophagic flux of gliomas and may demand different autophagic interference to achieve radio/chemosensitisation.

It seems that the interfering autophagy may indeed help us make a difference in the treatment of gliomas and glioblastomas. A hypothetical scheme for intervention targeting autophagy aiming to radiosensitisation is shown in [Figure 1](#fig1){ref-type="fig"}. Inducers of autophagy, like mTOR inhibitors available in the clinical practice ([@bib42]), can lead to a functional autophagic death when combined with standard radiotherapy and a schedule of continuous low daily dose of TMZ. Pretreatment of tumours with autophagy inducers, followed by hypofractionated radiotherapy and or high daily dose schedules of TMZ, in combination with late phase autophagy blockers, could enhance antineoplastic efficacy by leading to non-functional autophagic death. Whether early phase autophagy blockers could be of value in the combination of agents that restore apoptotic death pathways with radiotherapy or TMZ is also a hypothesis to study. Important issues remain, however, unresolved. One key question that has to be answered is whether radiotherapy and TMZ trigger a functional autophagic response or they just deregulate autophagy resulting in non-degradable autophagosome accumulation. This demands studies of monitoring the autophagic flux and lysosomal kinetics in cell lines after escalated doses of radiotherapy or TMZ, as dose schedule may be a principal factor defining the type of autophagic response.

Another important issue to resolve is the characterisation of the autophagic activity and response tendency of the tumour itself. Not all gliomas or glioblastomas are the same as, indeed, some of them are more radiosensitive than others. Assessment of the expression status of autophagy-blocking pathways such as Akt/mTOR may help to identify tumours of defective autophagy, the radiosensitivity of which may increase by specific Akt/mTOR inhibitors. As beclin 1 protein is downregulated in a large percentage of gliomas, detection of hypermethylated *Beclin 1* gene or other autophagy-initiating proteins may reveal targets for demethylating agent administration so that subsequent interference with autophagy inducers may become beneficial. Extensive expression of LC3A-positive stone-like structures may characterise tumours with functional autophagy that may benefit from concurrent radiotherapy with either early autophagy and DNA-repair blockers or autophagy induction therapy with mTOR inhibitors (depending upon radiotherapy fractionation).

Assessment of the content of CD133-positive compartment can be easily performed in immunohistochemistry of biopsies. Pretreatment of these patients with differentiation-inducing agents such as histone deacetylase inhibitors may prove a useful preradiotherapy policy. Silencing of stem-cell-specific genes, such as *Sirtuin 1*, or apoptosis restoration treatments, such as caspase or IL-24 adenoviruses, may also be of value in these cases.

Conclusion
==========

Malignant glioma is probably a unique model of non-metastasising disease that kills the majority of patients through local growth. It consists, therefore, of one of the biggest challenges in radiation therapy, especially nowadays when novel radiotherapy techniques allow the delivery of high dose per fraction to the tumour at the same time reducing the dose to the surrounding normal brain tissue. Whether hypofractionation that would block the autophagy flux, even in radioresistant cell lines, can be effectively combined with late autophagy blockers to exploit a non-functional autophagic death is a question that deserves investigation. Temozolomide is an important drug when combined with radiotherapy, or even for relapsed tumours after radiotherapy, and just like radiotherapy kills glioma cells through autophagic death. The combination of mTOR inhibitors (intensifiers or autophagy) with low daily dose of TMZ during standard radiotherapy or after failure of radiotherapy, aiming to trigger functional autophagic death, may also be a promising approach. Modulation of radiation or of TMZ autophagic response appears one of the most promising approaches to prolong survival and to better understand the glioblastoma therapy riddle, but important insights demanded to create a reliable concept are still missing.
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